Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity (2016 - 2026)

Gyre Therapeutics has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $166.1 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 32.48% to $166.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $608.0 million through Dec 2025, up 23.17% year-over-year, with the annual reading at $166.1 million for FY2025, 32.48% up from the prior year.
  • Liabilities and Shareholders Equity was $166.1 million for Q4 2025 at Gyre Therapeutics, up from $159.4 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $166.1 million in Q4 2025 and troughed at $10.0 million in Q3 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $109.2 million (2021), against an average of $92.7 million.
  • Year-over-year, Liabilities and Shareholders Equity plummeted 85.13% in 2023 and then surged 1156.92% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $55.7 million in 2021, then soared by 52.26% to $84.8 million in 2022, then skyrocketed by 37.5% to $116.5 million in 2023, then increased by 7.61% to $125.4 million in 2024, then soared by 32.48% to $166.1 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Liabilities and Shareholders Equity are $166.1 million (Q4 2025), $159.4 million (Q3 2025), and $152.6 million (Q2 2025).